



**ESPS PEER-REVIEW REPORT**

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 25812

**Title:** Glucose deprivation induces chemoresistance in colorectal cancer cells by increasing ATF4 expression

**Reviewer’s code:** 00742509

**Reviewer’s country:** Japan

**Science editor:** Ya-Juan Ma

**Date sent for review:** 2016-03-24 14:44

**Date reviewed:** 2016-04-29 13:39

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

**COMMENTS TO AUTHORS**

Authors described the GD-induced chemoresistance mechanism in CRC via ATF4 signaling and MDR1 induction. These data clarified the new therapeutic strategy to overcome the GD-induced refractory CRC in the clinic. This report is intriguing and meets the criteria of this journal, and may be acceptable after proper revision. Query 1. In abstract, authors should describe the spelling of abbreviation such as GD, CRC and MRD. 2. MDR should be used as only gene name MDR1, not used for abbreviation of multidrug resistance. 3. Authors described the GD condition as 1.5 mmol/l glucose. So glucose concentration of normal condition should be described in materials and methods section, too. 4. In figure 1b, F-FU should be revised. If authors describe the apoptotic rate as %, please check the number. Moreover, if authors used annexin V to evaluate apoptotic cell, please show the data of FACS. If not, the legend should be revised. 5. In figure3c, apoptotic induction by anticancer drug is weak. Authors should show the data of no treatment and chemo-treated data in normal condition as control. 6. In figure3 legend, authors described the MDR1 expression using RT-PCR, however, the data was not shown. 7. In figure4, please clarify what cells were used in



## BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

---

Figure 4 legend. 8. Validation of ATF4 overexpression and suppression by WB should be shown in figure5 as main data. Figure4d or Figure5 should include the mock and transfectant with and without chemo-treatment. 9. pGipZ might be better to be revised as mock or vehicle in the figures. 10 In figure2b, authors should explain what was treated in these cells. Moreover, authors described the p-PERK induction by GD, however, mRNA level of PERK as strongly induced by GD. Why the total PERK was not enhanced by GD in figure2b. Please explain this difference.